Array BioPharma Inc. (Nasdaq: ARRY) reported positive results from Part 1 of a Phase 3 COLUMBUS study of LGX818 to treat patients with BRAF-mutant melanoma sending the stock price soaring $2.96 to close at $6.61.
Array BioPharma reports upbeat study results
September 26, 2016 at 17:30 PM EDT